{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:57:13Z","timestamp":1790722633888,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["2023SCZ46"],"award-info":[{"award-number":["2023SCZ46"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01103-w","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T08:34:17Z","timestamp":1773909257000},"page":"754-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can pelvic lymph node dissection be spared in intermediate-risk prostate cancer patients with negative PSMA PET scan? A systematic review and diagnostic meta-analysis"],"prefix":"10.1038","volume":"29","author":[{"given":"Qi-Chang","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yin","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6917-1316","authenticated-orcid":false,"given":"Bin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"1103_CR1","doi-asserted-by":"publisher","first-page":"e2429760","DOI":"10.1001\/jamanetworkopen.2024.29760","volume":"7","author":"Diven MA","year":"2024","unstructured":"Diven MA, Tshering L, Ma X, Hu JC, Barbieri C, McClure T, et al. Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2024;7:e2429760.","journal-title":"JAMA Netw Open"},{"key":"1103_CR2","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/JU.0000000000004659","volume":"214","author":"A Eraky","year":"2025","unstructured":"Eraky A, Tillu N, Ben-David R, Hug B, Jodka H, Agarwal Y, et al. Diagnostic Accuracy of [(18)F]-DCFPyL Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computerized Tomography in Intermediate-Risk Prostate Cancer Undergoing Radical Prostatectomy: Is Pelvic Lymph Node Dissection Still Necessary? J Urol. 2025;214:365\u201373.","journal-title":"J Urol"},{"key":"1103_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CU9.0000000000000132","volume":"16","author":"RS Flammia","year":"2022","unstructured":"Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Sorce G, Tian Z, et al. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries. Curr Urol. 2022;16:191\u20136.","journal-title":"Curr Urol"},{"key":"1103_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2021.08.001","volume":"5","author":"A Stabile","year":"2022","unstructured":"Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol. 2022;5:1\u201317.","journal-title":"Eur Urol Oncol"},{"key":"1103_CR5","doi-asserted-by":"crossref","unstructured":"Song D, Malshy K, Messing EM, Joseph JV, Bandari J. Excluding PLND in favourable intermediate-risk prostate cancer: a PSMA-PET-directed perspective. Nature Rev Urol. 2025;13:6534.","DOI":"10.1038\/s41585-025-01105-8"},{"key":"1103_CR6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.23736\/S2724-6051.25.06510-3","volume":"77","author":"A Orsini","year":"2025","unstructured":"Orsini A, Cicchetti R, Digiacomo A, De Archangelis R, Basconi M, Litterio G, et al. Avoiding pelvic lymph node dissection in intermediate-risk prostate cancer with negative PSMA PET: a step toward personalized surgery. Minerva Urol Nephrol. 2025;77:422\u20134.","journal-title":"Minerva Urol Nephrol"},{"key":"1103_CR7","first-page":"785","volume":"76","author":"F Zattoni","year":"2024","unstructured":"Zattoni F, Carletti F, Reitano G, Novara G, Dal Moro F. PSMA PET vs. surgery: redefining lymph node staging in prostate cancer. Minerva Urol Nephrol. 2024;76:785\u20137.","journal-title":"Minerva Urol Nephrol"},{"key":"1103_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.prnil.2024.03.002","volume":"12","author":"S Morizane","year":"2024","unstructured":"Morizane S, Takenaka A. Current status and therapeutic value of extended pelvic lymph node dissection during radical prostatectomy for prostate cancer. Prostate Int. 2024;12:117\u201327.","journal-title":"Prostate Int"},{"key":"1103_CR9","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/JU.0000000000000504","volume":"203","author":"F Preisser","year":"2020","unstructured":"Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, et al. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D\u2019Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. J Urol. 2020;203:338\u201343.","journal-title":"J Urol"},{"key":"1103_CR10","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1111\/bju.16872","volume":"136","author":"J Carll","year":"2025","unstructured":"Carll J, Shi W, Perera M, Lawrentschuk N, Chengodu T, Woon D. Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer. BJU Int. 2025;136:800\u20134.","journal-title":"BJU Int"},{"key":"1103_CR11","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet"},{"key":"1103_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, et al. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2023;84:36\u201348.","journal-title":"Eur Urol"},{"key":"1103_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.euo.2020.08.012","volume":"5","author":"AT Lenis","year":"2022","unstructured":"Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-na\u00efve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. Eur Urol Oncol. 2022;5:544\u201352.","journal-title":"Eur Urol Oncol"},{"key":"1103_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000515651","volume":"106","author":"D Kopp","year":"2022","unstructured":"Kopp D, Kopp J, Bernhardt E, Manka L, Beck A, Gerullis H, et al. 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography-Based Primary Staging and Histological Correlation after Extended Pelvic Lymph Node Dissection in Intermediate-Risk Prostate Cancer. Urol Int. 2022;106:56\u201362.","journal-title":"Urol Int"},{"key":"1103_CR15","doi-asserted-by":"publisher","first-page":"639","DOI":"10.23736\/S2724-6051.25.06470-5","volume":"77","author":"M Bauckneht","year":"2025","unstructured":"Bauckneht M, Checcucci E, Lanfranchi F, Cisero E, Rizzo A, Scuderi S, et al. The added value of PSMA PET to nomograms in identifying optimal candidates for extended pelvic lymph node dissection in intermediate-risk prostate cancer patients. Minerva Urol Nephrol. 2025;77:639\u201346.","journal-title":"Minerva Urol Nephrol"},{"key":"1103_CR16","doi-asserted-by":"crossref","unstructured":"Incesu RB, Preisser F, Nohe F, Maurer T, Graefen M, Tilki D. Negative PSMA PET can be used to avoid unnecessary pelvic lymph node dissection in intermediate risk prostate cancer. Prostate Cancer Prostatic Diseases 2025;28:874\u20138.","DOI":"10.1038\/s41391-024-00930-z"},{"key":"1103_CR17","doi-asserted-by":"crossref","unstructured":"Evangelista L, Guglielmo P, Giacoppo G, Setti L, Aric\u00f2 D, Muraglia L, et al. The Evaluation of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography for Initial Staging in Intermediate-Risk Prostate Cancer Patients: A Retrospective Multicenter Analysis. Diagnostics 2024;14:2751.","DOI":"10.3390\/diagnostics14232751"},{"key":"1103_CR18","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2011.10.044","volume":"61","author":"A Briganti","year":"2012","unstructured":"Briganti A, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol. 2012;61:480\u20137.","journal-title":"Eur Urol"},{"key":"1103_CR19","doi-asserted-by":"publisher","first-page":"m2632","DOI":"10.1136\/bmj.m2632","volume":"370","author":"JP Salameh","year":"2020","unstructured":"Salameh JP, Bossuyt PM, McGrath TA, Thombs BD, Hyde CJ, Macaskill P, et al. Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist. BMJ. 2020;370:m2632.","journal-title":"BMJ"},{"key":"1103_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"PF Whiting","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529\u201336.","journal-title":"Ann Intern Med"},{"key":"1103_CR21","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00345-020-03131-0","volume":"38","author":"J Kopp","year":"2020","unstructured":"Kopp J, Kopp D, Bernhardt E, Manka L, Beck A, Gerullis H, et al. 68Ga-PSMA PET\/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy. World J Urol. 2020;38:3085\u201390.","journal-title":"World J Urol"},{"key":"1103_CR22","doi-asserted-by":"crossref","unstructured":"\u00d6zman O, Veerman H, Contieri R, Droghetti M, Donswijk ML, Hagens MJ, et al. Staging Accuracy and Prognostic Value of Prostate-Specific Membrane Antigen PET\/CT Strongly Depends on Lymph Node Tumor Burden. J Clin Med. 2024;13:6534.","DOI":"10.3390\/jcm13216534"},{"key":"1103_CR23","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1007\/s00259-025-07241-y","volume":"52","author":"TD Van Bergen","year":"2025","unstructured":"Van Bergen TD, Braat A, Hermsen R, Heetman JG, Wever L, Lavalaye J, et al. External validation of nomograms including PSMA PET information for the prediction of lymph node involvement of prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:3744\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1103_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/pros.24884","volume":"85","author":"B Esen","year":"2025","unstructured":"Esen B, Seymen H, Armutlu A, Koseoglu E, Aykanat IC, Zoro\u011flu H, et al. Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate-Risk Prostate Cancer Patients With Node-Negative PSMA PET. Prostate. 2025;85:777\u201383.","journal-title":"Prostate"},{"key":"1103_CR25","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, et al. Diagnostic Performance and Safety of Positron Emission Tomography with (18)F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE). Eur Urol. 2023;84:361\u201370.","journal-title":"Eur Urol"},{"key":"1103_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00918-7","volume":"12","author":"J Ingvar","year":"2022","unstructured":"Ingvar J, Hvittfeldt E, Tr\u00e4g\u00e5rdh E, Simoulis A, Bjartell A. Assessing the accuracy of [(18)F]PSMA-1007 PET\/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients. EJNMMI Res. 2022;12:48.","journal-title":"EJNMMI Res"},{"key":"1103_CR27","doi-asserted-by":"publisher","first-page":"E381","DOI":"10.5489\/cuaj.7739","volume":"16","author":"S Dekalo","year":"2022","unstructured":"Dekalo S, Kuten J, Campbell J, Mintz I, Bar-Yosef Y, Keizman D, et al. 68)Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography for patients with favorable intermediate-risk prostate cancer. Can Urol Assoc J. 2022;16:E381\u20135.","journal-title":"Can Urol Assoc J"},{"key":"1103_CR28","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1007\/s00261-020-02640-1","volume":"45","author":"M Frumer","year":"2020","unstructured":"Frumer M, Milk N, Rinott Mizrahi G, Bistritzky S, Sternberg I, Leibovitch I, et al. A comparison between (68)Ga-labeled prostate-specific membrane antigen-PET\/CT and multiparametric MRI for excluding regional metastases prior to radical prostatectomy. Abdom Radiol. 2020;45:4194\u2013201.","journal-title":"Abdom Radiol"},{"key":"1103_CR29","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/JU.0000000000000053","volume":"201","author":"JW Yaxley","year":"2019","unstructured":"Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, et al. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with (68)Ga-PSMA Positron Emission Tomography\/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology. J Urol. 2019;201:815\u201320.","journal-title":"J Urol"},{"key":"1103_CR30","doi-asserted-by":"crossref","unstructured":"Incesu RB, Preisser F, Pompe RS, Nohe F, Mandel P, Maurer T, et al. Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy. Eur Urol Focus 2025;11:582\u20137.","DOI":"10.1016\/j.euf.2025.01.015"},{"key":"1103_CR31","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.29603","volume":"222","author":"TH Kim","year":"2024","unstructured":"Kim TH, Woo S. How Systematic Review Can Shape Clinical Practice in Radiology. AJR Am J Roentgenol. 2024;222:e2329603.","journal-title":"AJR Am J Roentgenol"},{"key":"1103_CR32","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","volume":"87","author":"E Mazzone","year":"2025","unstructured":"Mazzone E, Cannoletta D, Quarta L, Chen DC, Thomson A, Barletta F, et al. A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment. Eur Urol. 2025;87:654\u201371.","journal-title":"Eur Urol"},{"key":"1103_CR33","doi-asserted-by":"crossref","unstructured":"Bonaddio J, Carll J, Eapen R, Sathianathen N, Lawrentschuk N. The role of PSMA PET\/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2025;137:49\u201357.","DOI":"10.1111\/bju.70015"},{"key":"1103_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024;86:148\u201363.","journal-title":"Eur Urol"},{"key":"1103_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/bju.70015","volume":"137","author":"J Bonaddio","year":"2026","unstructured":"Bonaddio J, Carll J, Eapen R, Sathianathen N, Lawrentschuk N. The role of PSMA PET\/CT in staging patients with intermediate-risk prostate cancer. BJU Int. 2026;137:49\u201357.","journal-title":"BJU Int"},{"key":"1103_CR36","doi-asserted-by":"publisher","first-page":"71.e71","DOI":"10.1016\/j.urolonc.2025.09.011","volume":"44","author":"BF Hartwieg","year":"2026","unstructured":"Hartwieg BF, Maurer T, Kniep C, Mandel P, Wenzel M, Falkenbach F, et al. Use of staging in intermediate-risk prostate cancer: A real-world data analysis. Urol Oncol. 2026;44:71.e71\u201371.e77.","journal-title":"Urol Oncol"},{"key":"1103_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/1097-0142(20010101)91:1<66::AID-CNCR9>3.0.CO;2-P","volume":"91","author":"L Cheng","year":"2001","unstructured":"Cheng L, Zincke H, Blute ML, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001;91:66\u201373.","journal-title":"Cancer"},{"key":"1103_CR38","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/01.ju.0000143448.04161.cc","volume":"172","author":"S Daneshmand","year":"2004","unstructured":"Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol. 2004;172:2252\u20135.","journal-title":"J Urol"},{"key":"1103_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bju.15881","volume":"131","author":"D Meijer","year":"2023","unstructured":"Meijer D, Ettema RH, van Leeuwen PJ, van der Kwast TH, van der Poel HG, Donswijk ML, et al. The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (PET\/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer. BJU Int. 2023;131:330\u20138.","journal-title":"BJU Int"},{"key":"1103_CR40","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.semradonc.2025.04.014","volume":"35","author":"J Pozin","year":"2025","unstructured":"Pozin J, Bhandari M, Valle L, Nickols NG, Kishan AU, Kamran SC, et al. The Evolving Management of Radiorecurrent Prostate Cancer. Semin Radiat Oncol. 2025;35:450\u201362.","journal-title":"Semin Radiat Oncol"},{"key":"1103_CR41","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet"},{"key":"1103_CR42","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ijrobp.2023.10.009","volume":"118","author":"CA Fink","year":"2024","unstructured":"Fink CA, Wegener D, Sauer LD, Lentz-Hommertgen A, Liermann J, M\u00fcller AC, et al. Pelvic Irradiation for Node-Positive Prostate Cancer After Prostatectomy: Long-Term Results of the Prospective PLATIN-4 and PLATIN-5 Trials. Int J Radiat Oncol Biol Phys. 2024;118:1011\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1103_CR43","doi-asserted-by":"crossref","unstructured":"Clinckaert A, Callens K, Cooreman A, Bijnens A, Moris L, Van Calster C, et al. The Prevalence of Lower Limb and Genital Lymphedema after Prostate Cancer Treatment: A Systematic Review. Cancers 2022;14:5667.","DOI":"10.3390\/cancers14225667"},{"key":"1103_CR44","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s00345-020-03322-9","volume":"39","author":"N Peilleron","year":"2021","unstructured":"Peilleron N, Seigneurin A, Herault C, Verry C, Bolla M, Rambeaud JJ, et al. External evaluation of the Briganti nomogram to predict lymph node metastases in intermediate-risk prostate cancer patients. World J Urol. 2021;39:1489\u201397.","journal-title":"World J Urol"},{"key":"1103_CR45","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.urology.2022.01.049","volume":"165","author":"JM Kuperus","year":"2022","unstructured":"Kuperus JM, Tobert CM, Semerjian AM, Qi J, Lane BR. Pelvic Lymph Node Dissection at Radical Prostatectomy for Intermediate Risk Prostate Cancer: Assessing Utility and Nodal Metastases Within a Statewide Quality Improvement Consortium. Urology. 2022;165:227\u201336.","journal-title":"Urology"},{"key":"1103_CR46","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/CU9.0000000000000290","volume":"19","author":"ON Gofrit","year":"2025","unstructured":"Gofrit ON, Orevi M, Ben-Haim S, Meuman T, Duvdevani M, Hidas G, et al. The relevance of nomograms for prediction of pelvic lymph node metastases in the prostate-specific membrane antigen (PSMA)-PET\/CT era. Curr Urol. 2025;19:353\u20136.","journal-title":"Curr Urol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01103-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01103-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:13Z","timestamp":1790719213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01103-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1103"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01103-w","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}